disease

FTD

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about FTD: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1193Connections

4Hypotheses

7Analyses

50Outgoing

50Incoming

6Experiments

9Debates

No summary available yet. View on Wiki →

No AI portrait yet

Disease Info

Phase	Phase 2
Status	Completed
Drug	Prednisone (various doses)
Patient Population	Patients with clinically probable bvFTD
Duration	12 weeks double-blind, followed by optional open-label extension
NCT Number	NCT00138602
Microglial Activation	Activated microglia in frontal and temporal cortices
Cytokine Elevation	Elevated IL-1β, TNF-α, and IL-6 in FTD brain tissue
Complement Activation	Increased complement cascade activation
Correlation with Symptoms	Neuroinflammation severity correlates with behavioral symptoms
Receptor Binding	Glucocorticoids bind to intracellular glucocorticoid receptors (GR) in cytoplasm
Gene Transcription	Modulates expression of anti-inflammatory proteins (e.g., IκB, annexin-1)
Associated Genes	ACHE, AD, AKT, AMYLOID, APOE, APP, BDNF, C9orf72
KG Connections	808 knowledge graph edges
Databases	OMIM Orphanet ClinicalTrials PubMed

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    FTD["FTD"] -->|"interacts"| FUS["FUS"]
    FTD["FTD"] -->|"interacts"| LC3["LC3"]
    FTD["FTD"] -->|"interacts"| OPTN["OPTN"]
    FTD["FTD"] -->|"interacts"| P62["P62"]
    FTD["FTD"] -->|"interacts"| SQSTM1["SQSTM1"]
    FTD["FTD"] -->|"interacts"| STING["STING"]
    ALS["ALS"] -->|"activates"| FTD["FTD"]
    NEURODEGENERATION["NEURODEGENERATION"] -->|"associated"| FTD["FTD"]
    C9ORF72["C9ORF72"] -->|"causes"| FTD["FTD"]
    AUTOPHAGY["AUTOPHAGY"] -->|"activates"| FTD["FTD"]
    style FTD fill:#ef5350,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (461)

Target	Relation	Type	Str
UBQLN2	associated_with	gene	0.80
HTT	interacts_with	gene	0.70
VCP	stabilizes	gene	0.70
VCP	expresses	gene	0.70
NRF2	interacts_with	gene	0.70
MAPT	interacts_with	gene	0.70
NEURONS	interacts_with	cell_type	0.70
TARDBP	associated_with	gene	0.70
FUS	associated_with	gene	0.70
VCP	associated_with	gene	0.70
LEWY BODY DEMENTIA	regulates	disease	0.70
LEWY BODY DEMENTIA	markers	disease	0.70
TREM2	activates	gene	0.70
LRRK2	interacts_with	gene	0.70
SIRT1	targets	gene	0.70
GRN	regulates	gene	0.70
NEURONS	expresses	cell_type	0.70
PROGRESSIVE SUPRANUCLEAR PALSY	regulates	disease	0.70
MACROPHAGE	regulates	cell_type	0.70
PSEN1	interacts_with	gene	0.70
GFAP	activates	gene	0.70
TFEB	regulates	gene	0.70
STING	markers	gene	0.70
MAPT	markers	gene	0.70
RIPK1	activates	gene	0.70
GRN	protects_against	gene	0.70
TREM2	markers	gene	0.70
NEURONS	degrades	cell_type	0.70
RAGE	causes	gene	0.70
RAGE	interacts_with	gene	0.70
GBA	interacts_with	gene	0.70
P53	causes	gene	0.65
MICROGLIA	regulates	cell_type	0.65
NEURON	contributes_to	cell_type	0.65
MICROGLIA	contributes_to	cell_type	0.65
TAU	causes	gene	0.65
NEURONS	phosphorylates	cell_type	0.65
NEURON	phosphorylates	cell_type	0.65
TAU	phosphorylates	gene	0.65
TREM2	contributes_to	gene	0.65
PARKIN	impairs	gene	0.65
PARKINSON'S DISEASE	impairs	disease	0.65
PARKINSON	impairs	disease	0.65
NEURON	regulates	cell_type	0.65
NEURON	expressed_in	cell_type	0.65
NEURONS	expressed_in	cell_type	0.65
NEURON	inhibits	cell_type	0.65
NOTCH	associated_with	gene	0.65
NEURONS	activates	cell_type	0.65
TREM2	associated_with	gene	0.65

Incoming (732)

Source	Relation	Type	Str
ALS	interacts_with	disease	1.00
ALS	activates	disease	1.00
PARKINSON'S DISEASE	associated_with	disease	1.00
ALZHEIMER'S DISEASE	associated_with	disease	1.00
ALS	associated_with	disease	1.00
TARDBP	associated_with	gene	1.00
TAU	associated_with	protein	0.98
ALS	causes	disease	0.98
ALS	regulates	disease	0.98
VCP	associated_with	gene	0.95
FUS	involved_in	protein	0.95
TARDBP	involved_in	protein	0.95
TARDBP	causes	protein	0.95
C9ORF72	risk_factor_for	gene	0.95
Tau 3R/4R Ratio	biomarker_for	biomarker	0.93
C9orf72 expansions	risk_factor_for	gene	0.90
Rbp Dysfunction	contributes_to	mechanism	0.90
Ftld	associated_with	disease	0.90
Als	associated_with	disease	0.90
Cryptic Hdgfl2	biomarker_for	biomarker	0.90
STING	associated_with	protein	0.90
TDP-43	causes	protein	0.90
Ggggcc Repeat Expansion	risk_factor_for	biomarker	0.90
TDP-43	implicated_in	protein	0.90
GGGGCC Repeat Expansion	associated_with	biomarker	0.90
C9ORF72	causes	gene	0.87
G3BP1	implicated_in	entity	0.85
FUS	associated_with	gene	0.82
MAPT	associated_with	gene	0.82
C9ORF72	implicated_in	gene	0.80
DIPEPTIDE REPEAT PROTEINS (DPRS)	causes	compound	0.80
C9ORF72 REPEAT RNA	causes	compound	0.80
P53	associated_with	gene	0.80
vesicle trafficking	associated_with	pathway	0.80
stress_granule_formation	contributes_to	pathway	0.80
AMYLOID	associated_with	protein	0.74
SOD1	associated_with	gene	0.74
GGGGCC_repeat	causes	genetic_variant	0.72
VESICLE_TRAFFICKING	associated_with	pathway	0.72
TDP43	associated_with	protein	0.72
LC3	activates	protein	0.72
CREB	targets	gene	0.70
BECN1	transports	gene	0.70
AMYOTROPHIC LATERAL SCLEROSIS	degrades	disease	0.70
AMYOTROPHIC LATERAL SCLEROSIS	expresses	disease	0.70
CORTICOBASAL DEGENERATION	associated_with	disease	0.70
C9ORF72	mediates	gene	0.70
C9ORF72	protects_against	gene	0.70
FRONTOTEMPORAL DEMENTIA	expresses	disease	0.70
ACHE	targets	gene	0.70

Targeting Hypotheses (4)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Microglial AIM2 Inflammasome as the Primary Driver of TDP-43	0.824	neurodegeneration	What are the mechanisms by which gut mic
Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurode	0.690	neurodegeneration	Gap 006 analysis (archived stub)
Stathmin-2 Splice Switching to Prevent Axonal Degeneration A	0.664	neurodegeneration	RNA binding protein dysregulation across
Nuclear TDP-43 Depletion Drives Synaptic Splicing Dysregulat	0.620	neurodegeneration	Gap 006 analysis (archived stub)

Mentioning Analyses (7)

Scientific analyses that reference this entity

test debate

neurodegeneration | 2026-04-15 | 0 hypotheses

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.720

RNA binding protein dysregulation across ALS FTD AD

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.664

How do pathological stress granules in neurodegeneration escape TRIM21/autophagy

neurodegeneration | 2026-04-06 | 7 hypotheses Top: 0.717

Gap 006 analysis (archived stub)

neurodegeneration | 2026-04-02 | 7 hypotheses Top: 0.760

Experiments (6)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FTD	validation	ALS	0.400	0.50	human	proposed	$2,730,000
Progranulin Replacement Therapy for FTD — Vector Development and Valid	clinical	ALS	0.400	0.50	human	proposed	$5,460,000
FTD Microglia Role: Protective vs Destructive Mechanism Study	validation	Neuroinflammation	0.400	0.50	human	proposed	$2,960,000
Frontal and Temporal Lobe Selective Vulnerability in FTD — Mechanisms	validation	Neurodegeneration	0.400	0.50	human	proposed	$3,000,000
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study	clinical	ALS	0.400	0.50	human	proposed	$6,550,000
Autophagy Enhancement Drug Screening for Neurodegeneration	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$6,550,000

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (9)

Multi-agent debates referencing this entity

Analysis for knowledge gap 006 in the neurodegeneration domain.

closed · Rounds: 4 · Score: 0.79 · 2026-04-22

The study shows TRIM21 and autophagy receptors can eliminate both physiological

closed · Rounds: 4 · Score: 0.75 · 2026-04-22

test debate [TARGET_ARTIFACT type=experiment id=exp-123]

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

The abstract reveals FUS has a chaperone-like function regulating TAZ condensate

closed · Rounds: 4 · Score: 0.81 · 2026-04-16

RNA binding protein dysregulation across ALS FTD AD

closed · Rounds: 4 · Score: 0.50 · 2026-04-13

RNA binding protein dysregulation across ALS FTD and AD

closed · Rounds: 4 · Score: 0.72 · 2026-04-12

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

closed · Rounds: 6 · Score: 0.84 · 2026-04-12

TDP-43 phase separation therapeutics for ALS-FTD

closed · Rounds: 4 · Score: 0.95 · 2026-04-11

RNA binding protein dysregulation across ALS FTD and AD

closed · Rounds: 4 · Score: 0.88 · 2026-04-06

FTD

Understanding Entity Pages

Wiki Pages (21)

Corticosteroids in FTD Trial

Frontotemporal Dementia (FTD)

Frontotemporal Dementia (FTD) Mechanistic Pathway

Epigenetic Dysregulation Comparison -- AD/PD/ALS/FTD/HD

Lipid Metabolism Dysfunction Comparison — AD/PD/ALS/FTD/HD

Autophagy-Lysosomal Impairment Comparison — AD/PD/ALS/FTD/HD

Neuroinflammation Across AD, PD, ALS, FTD, and HD

ALS-FTD Spectrum

Autophagy Failure Comparison -- AD/PD/ALS/FTD/HD

FTD Tau Subtypes Comparison: 3R vs 4R Tauopathies

FTD-ALS Spectrum

C9orf72→RNA/Dipeptide Repeat Pathology→ALS/FTD — Causal Chain

Mechanism: Progranulin Loss and TDP-43 Pathology in FTD

Neuroinflammation Comparison — AD/PD/ALS/FTD/HD

FUS Gene-Mechanism-Therapy Causal Chain — ALS/FTD

GRN Progranulin FTD Causal Chain

Neurovascular Coupling Disease Comparison — AD/PD/ALS/FTD/HD

Mitochondrial Dysfunction in ALS-FTD Spectrum

VCP→TDP-43→ALS/FTD Causal Chain

AD-FTD Tau-TDP-43 Overlap: Mechanism Comparison

Behavioral Variant FTD: Network and Molecular Mechanisms

Pathway Diagram

Outgoing (461)

Incoming (732)

Targeting Hypotheses (4)

Mentioning Analyses (7)

test debate

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes

RNA binding protein dysregulation across ALS FTD AD

How do pathological stress granules in neurodegeneration escape TRIM21/autophagy

Gap 006 analysis (archived stub)

RNA binding protein dysregulation across ALS FTD and AD

TDP-43 phase separation therapeutics for ALS-FTD

Experiments (6)

Related Papers (0)

Debates (9)

Analysis for knowledge gap 006 in the neurodegeneration domain.

The study shows TRIM21 and autophagy receptors can eliminate both physiological

test debate [TARGET_ARTIFACT type=experiment id=exp-123]

The abstract reveals FUS has a chaperone-like function regulating TAZ condensate

RNA binding protein dysregulation across ALS FTD AD

RNA binding protein dysregulation across ALS FTD and AD

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

TDP-43 phase separation therapeutics for ALS-FTD

RNA binding protein dysregulation across ALS FTD and AD